Thy1-SNCA Clu Knockout Mouse Model for Earlier PD Phenotypes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing Parkinson's disease (PD) animal models fail to accurately replicate both motor and non-motor pathological characteristics due to late onset of symptoms and inconsistencies with human PD pathology, leading to inefficiencies in research and drug screening.
Innovation Solution
A Thy1-SNCA;Clu gene knockout mouse model is developed by crossing Thy1-SNCA mice with Clu-KO mice and backcrossing to create Thy1-SNCA;Clu−/− mice, utilizing CRISPR/Cas9 technology to knockout the Clu gene, which mediates α-syn degradation and accelerates PD-like symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional PD animal models (MPTP, 6-OHDA, rotenone, transgenic models) are used, then motor disorder characteristics can be replicated, but non-motor symptoms and accurate PD pathology cannot be fully simulated
Solution Approach 1:
The patent combines the Thy1-SNCA transgenic model with Clu gene knockout to create a composite model (Thy1-SNCA;Clu−/−) that integrates multiple PD pathology features. This merging of two independent model systems allows simultaneous replication of motor disorders, non-motor symptoms, and accurate PD pathology including Lewy body formation and dopaminergic neuron loss.
Solution Approach 2:
The patent creates a composite animal model by crossing Thy1-SNCA mice with Clu-KO mice to generate F1 and F2 generations with specific genotypes. This composite genetic makeup produces a model that exhibits combined phenotypic characteristics of both parent lines, achieving comprehensive PD pathology representation that neither single model could achieve alone.
2Quantity of substance
If Thy1-SNCA mice are used, then α-syn overexpression is achieved, but PD-like symptoms appear late (around 14 months of age)
Solution Approach 1:
The patent applies preliminary action by knocking out the Clu gene before the development of PD symptoms in the Thy1-SNCA background. The Clu knockout is established in the mouse strain prior to observing PD phenotypes, thereby accelerating the onset of symptoms and reducing the experimental time required to observe PD-like characteristics.
Solution Approach 2:
The patent changes the genetic parameter by introducing a Clu gene knockout into the Thy1-SNCA model. This genetic modification alters the disease progression timeline, causing PD-like symptoms to appear significantly earlier (around 6 months of age) compared to wild-type Thy1-SNCA mice, thereby reducing the experimental period.
3Productivity
If existing PD models are used, then research can be conducted, but experimental period is long and model stability is poor
Solution Approach 1:
The patent performs preliminary genetic modification (Clu knockout) before symptom onset to accelerate disease progression. This preliminary action enables researchers to observe PD phenotypes much earlier, significantly shortening the experimental period and improving research efficiency.
Solution Approach 2:
The patent modifies the disease progression parameter by combining Thy1-SNCA with Clu knockout, which changes the timeline from 14 months to approximately 6 months for symptom onset. This parameter change reduces the experimental duration while maintaining model stability and phenotypic accuracy.
Data Source
AI summary
A construction method and use of a Thy1-SNCA;Clu gene knockout mouse model are provided. The construction method includes: subjecting a Thy1-SNCA mouse to crossing with a Clu-KO mouse to obtain an F1 generation, and then conducting identification to obtain a Thy1-SNCA;Clu−/+ mouse; and subjecting the Thy1-SNCA;Clu−/+ mouse to backcrossing with the Clu-KO mouse to obtain an F2 generation, and then conducting identification to obtain a mouse with a target genotype, recorded as a Thy1-SNCA;Clu−/− mouse. The Thy1-SNCA;Clu−/− mouse can effectively shorten a time point for the onset of Parkinson's disease (PD)-like movement disorders, thereby shortening an experimental period. The mouse can provide more model mouse options for PD research.